According to Orient's announcement, three departments including the National Health and Health Commission issued a notice that the company's main drug, didroprogesterone tablets, was added to the “National Essential Drug Catalogue”. The catalogue will take effect on September 1, 2026. Didrogesterone tablets can be used to treat diseases caused by endogenous progesterone deficiency. This addition to the basic drug catalogue is beneficial to drug promotion and has a positive effect on the company's market expansion and long-term development, but subsequent sales are affected by multiple factors, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.